Age at onset (years)
|
64.2±9.5
|
64.5±8.7
|
0.231
|
CRC locationa, n (%)
| | |
0.331
|
Left
|
52 (52.0)
|
47 (45.2)
| |
Right
|
48 (48.0)
|
57 (54.8)
| |
Metastatic sites, n (%)
| | |
0.848
|
Intra-abdominal
|
25 (25.0)
|
27 (26.0)
| |
Lung
|
14 (14.0)
|
16 (15.4)
| |
Bone
|
22 (22.0)
|
26 (25.0)
| |
Live
|
25 (25.0)
|
17 (16.3)
| |
Brain
|
7 (7.0)
|
9 (8.7)
| |
Other
|
11 (11.0)
|
1413.5)
| |
Serum lactate dehydrogenase level, n (%)
| | |
0.428
|
Normalb
|
33 (33.0)
|
29 (27.9)
| |
Above normal
|
67 (67.0)
|
75 (72.1)
| |
Portal vein invasion, n (%)
| | |
0.733
|
Yes
|
67 (67.0)
|
72 (69.2)
| |
No
|
33 (33.0)
|
32 (30.8)
| |
Duration of treatment (months)
|
27.2±11.4
|
27.3±12.5
|
0.106
|
Hepatic encephalopathy, n (%)
|
0 (0.0)
|
0 (0)
|
1.000
|
ECOG PS, n (%)
| | |
0.860
|
0
|
43 (43.0)
|
46 (44.2)
| |
1
|
57 (57.0)
|
58 (55.8)
| |
Number of metastatic sites, n (%)
| | |
0.454
|
3
|
13 (13.0)
|
20 (19.2)
| |
> 3
|
72 (72.0)
|
68 (65.4)
| |
Unknown
|
15 (15.0)
|
16 (15.4)
| |